AR102926A1 - Composiciones anticancerosas - Google Patents

Composiciones anticancerosas

Info

Publication number
AR102926A1
AR102926A1 ARP150103982A ARP150103982A AR102926A1 AR 102926 A1 AR102926 A1 AR 102926A1 AR P150103982 A ARP150103982 A AR P150103982A AR P150103982 A ARP150103982 A AR P150103982A AR 102926 A1 AR102926 A1 AR 102926A1
Authority
AR
Argentina
Prior art keywords
solid dispersion
hpmcas
pharmaceutical formulation
rna
target compositions
Prior art date
Application number
ARP150103982A
Other languages
English (en)
Original Assignee
Aragon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aragon Pharmaceuticals Inc filed Critical Aragon Pharmaceuticals Inc
Publication of AR102926A1 publication Critical patent/AR102926A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Reivindicación 1: Una dispersión sólida que comprende ARN-509 y HPMCAS. Reivindicación 10: Una partícula que consiste en una dispersión sólida tal como se define en cualquiera de las reivindicaciones anteriores. Reivindicación 12: Una formulación farmacéutica que comprende un vehículo farmacéuticamente aceptable y una dispersión sólida de acuerdo con cualquiera de las reivindicaciones 1 a 9. Reivindicación 16: Un proceso para preparar la dispersión sólida de acuerdo con la reivindicación 8 que comprende las etapas de mezclar ARN-509 y HPMCAS en un disolvente adecuado y someter dicha mezcla a deshidratación por aspersión. Reivindicación 19: El uso de la formulación farmacéutica de acuerdo con cualquiera de las reivindicaciones 12 a 15 para la preparación de un medicamento para el tratamiento del cáncer de próstata.
ARP150103982A 2014-12-05 2015-12-04 Composiciones anticancerosas AR102926A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14196594 2014-12-05

Publications (1)

Publication Number Publication Date
AR102926A1 true AR102926A1 (es) 2017-04-05

Family

ID=52006906

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150103982A AR102926A1 (es) 2014-12-05 2015-12-04 Composiciones anticancerosas

Country Status (22)

Country Link
US (3) US20170360754A1 (es)
EP (1) EP3226841B1 (es)
JP (2) JP6937692B2 (es)
KR (2) KR102348320B1 (es)
CN (2) CN106999431B (es)
AR (1) AR102926A1 (es)
AU (3) AU2015358490B2 (es)
BR (1) BR112017011788A2 (es)
CA (1) CA2969656A1 (es)
CL (1) CL2017001371A1 (es)
CO (1) CO2017005572A2 (es)
CR (1) CR20170216A (es)
EA (1) EA201791222A1 (es)
IL (2) IL252323B (es)
MA (1) MA41107A (es)
MX (2) MX2017007203A (es)
NZ (1) NZ770528A (es)
PH (1) PH12017500964A1 (es)
SG (1) SG11201704267VA (es)
TW (2) TWI702966B (es)
UA (1) UA120950C2 (es)
WO (1) WO2016090098A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104661658A (zh) 2012-09-26 2015-05-27 阿拉贡药品公司 用于治疗非转移性去势抵抗性前列腺癌的抗雄激素
EP3226843B1 (en) 2014-12-05 2021-05-26 Aragon Pharmaceuticals, Inc. Anticancer compositions
MA41107A (fr) * 2014-12-05 2017-10-10 Aragon Pharmaceuticals Inc Compositions anti-cancéreuses
CN111479560A (zh) 2017-10-16 2020-07-31 阿拉贡药品公司 用于治疗非转移性去势难治性前列腺癌的抗雄激素
WO2020144649A1 (en) 2019-01-10 2020-07-16 Aragon Pharmaceuticals, Inc. Pharmaceutical composition comprising enzalutamide dispersed in apple sauce
CN113365623A (zh) 2019-01-30 2021-09-07 阿拉贡药品公司 用于治疗转移性去势敏感性前列腺癌的抗雄激素
WO2020157704A1 (en) 2019-01-30 2020-08-06 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
EP3811932A1 (en) 2019-10-22 2021-04-28 Zentiva K.S. Dosage form of apalutamide
EP4054572A1 (en) 2019-11-04 2022-09-14 Aragon Pharmaceuticals, Inc. Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment
WO2021245285A1 (en) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
TW202228794A (zh) 2020-09-04 2022-08-01 美商艾瑞岡醫藥公司 用於治療前列腺癌之方法
WO2022195407A1 (en) 2021-03-19 2022-09-22 Aragon Pharmaceuticals, Inc. Methods for treating prostate cancer
WO2023122842A1 (es) * 2021-12-31 2023-07-06 Gador Limitada Proceso para la preparación de apalutamida, intermediarios de sintesis y la dispersion solida amorfa que la contiene
WO2023152611A1 (en) 2022-02-11 2023-08-17 Aragon Pharmaceuticals, Inc. Apalutamide and relugolix for the treatment of prostate cancer
WO2023209555A1 (en) 2022-04-26 2023-11-02 Aragon Pharmaceuticals, Inc. Approved drug products and methods for treating prostate cancer
WO2024189186A1 (en) 2023-03-16 2024-09-19 Bayer Consumer Care Ag Androgen receptor antagonists for the treatment of patients with biochemical recurrence of hormone sensitive prostate cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0901786B1 (en) * 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
CA2450762A1 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers
SE0103424D0 (sv) * 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
EP1469830A2 (en) * 2002-02-01 2004-10-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
ES2593379T3 (es) * 2006-03-27 2016-12-09 The Regents Of The University Of California Modulador del receptor de andrógenos para el tratamiento del cáncer de próstata y enfermedades asociadas con el receptor de andrógenos
WO2013152342A1 (en) * 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
CA3008345C (en) * 2012-06-07 2019-10-22 Aragon Pharmaceuticals, Inc. Crystalline forms of an androgen receptor modulator
EP2888293B1 (en) * 2012-08-24 2019-05-08 Dow Global Technologies LLC Novel hydroxyalkyl methyl cellulose acetate succinates
CN109897004A (zh) * 2012-09-11 2019-06-18 麦迪威森前列腺医疗有限责任公司 恩杂鲁胺制剂
CN104661658A (zh) * 2012-09-26 2015-05-27 阿拉贡药品公司 用于治疗非转移性去势抵抗性前列腺癌的抗雄激素
BR112016002970A2 (pt) * 2013-08-12 2017-09-12 Tokai Pharmaceuticals Inc biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio
CA2940984A1 (en) * 2014-02-05 2015-08-13 Lek Pharmaceuticals D.D. Solid pharmaceutical compositions of androgen receptor antagonists
MA41107A (fr) * 2014-12-05 2017-10-10 Aragon Pharmaceuticals Inc Compositions anti-cancéreuses

Also Published As

Publication number Publication date
JP6937692B2 (ja) 2021-09-22
CN106999431A (zh) 2017-08-01
MX2017007203A (es) 2017-08-28
IL279833B (en) 2022-03-01
JP2020143069A (ja) 2020-09-10
IL252323B (en) 2021-04-29
KR20200141533A (ko) 2020-12-18
AU2015358490B2 (en) 2021-04-08
UA120950C2 (uk) 2020-03-10
KR20170086656A (ko) 2017-07-26
TW201630592A (zh) 2016-09-01
BR112017011788A2 (pt) 2017-12-26
US20240293374A1 (en) 2024-09-05
EP3226841A1 (en) 2017-10-11
CL2017001371A1 (es) 2018-01-05
CR20170216A (es) 2017-08-30
NZ770528A (en) 2024-03-22
PH12017500964A1 (en) 2017-10-18
SG11201704267VA (en) 2017-06-29
EP3226841B1 (en) 2024-10-09
JP2017536398A (ja) 2017-12-07
TW202031248A (zh) 2020-09-01
CN114886852A (zh) 2022-08-12
KR102348320B1 (ko) 2022-01-10
WO2016090098A1 (en) 2016-06-09
CA2969656A1 (en) 2016-06-09
NZ731963A (en) 2024-03-22
MA41107A (fr) 2017-10-10
TWI754258B (zh) 2022-02-01
AU2023202710A1 (en) 2023-05-18
TWI702966B (zh) 2020-09-01
IL279833A (en) 2021-01-31
IL252323A0 (en) 2017-07-31
CO2017005572A2 (es) 2017-09-20
AU2015358490A1 (en) 2017-06-08
US20170360754A1 (en) 2017-12-21
US20230233529A1 (en) 2023-07-27
JP7174006B2 (ja) 2022-11-17
EA201791222A1 (ru) 2017-09-29
AU2021201979B2 (en) 2023-02-02
MX2021013965A (es) 2022-01-04
CN106999431B (zh) 2022-03-04
AU2021201979A1 (en) 2021-04-29

Similar Documents

Publication Publication Date Title
AR102926A1 (es) Composiciones anticancerosas
CL2018000706A1 (es) Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer.
CL2016001629A1 (es) Compuestos tricíclicos como agentes anticancerígenos
UY37435A (es) Pirrolidinas sustituidas y métodos para usarlas
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
EA033266B1 (ru) Гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
CL2014003444A1 (es) Compuestos derivados tienopirimidina; proceso de preparacion; composicion farmaceutica que los comprende; combinacion farmaceutica; uso en el tratamiento de canceres y enfermedades autoinmunes.
CL2014001829A1 (es) Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer.
BR112018011929A2 (pt) composto, composição farmacêutica, métodos para tratamento da infecção viral da hepatite c, de carcinoma basocelular, de ceratose actínica, da infecção viral de papiloma genital e da infecção viral de hepatite c, processo para preparação de um composto, e, uso de um composto
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
NZ728072A (en) Modulators of toll-like receptors for the treatment of hiv
PE20160930A1 (es) Nanoparticulas polimericas terapeuticas y metodos para su elaboracion y uso.
AR091220A1 (es) Metodos para tratar cancer usando antagonistas de union a pd-1 axis y antagonistas de vegf
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
AR102924A1 (es) Composiciones anticancerosas
CL2014002505A1 (es) Compuestos derivados de piridopirimidina substituida, como inhibidores de flt3; formulacion farmaceutica que los comprende; y su uso para el tratamiento de tumores hematologicos malignos tal como leucemias, enfermedades autoinmunes y tumores solidos malignos.
EA201692334A1 (ru) Кортикостероидные композиции для местного применения
CR20150604A (es) Proceso para la preparación de eritrocitos cargados con una o más sustancias de interés farmacéutico y eritrocitos así obtenidos
CR20180228A (es) Terapia adjunta con 25-hidroxi vitamina d y articulos de la misma
CL2014002604A1 (es) Compuestos derivados de 3,5-disustituido-3h-imidazo[4,5-b]piridina y 3,5-disustituido-3h-[1,2,3]triazolo[4,5-b]piridina, como moduladores de proteina kinasa c-met; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer, tal como carcinoma y sarcoma musculoesqueletico.
WO2015033302A3 (en) Fulvestrant compositions
CO2016003340A2 (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
CL2016001937A1 (es) Compuestos de benzopirano funcionalizados y uso de los mismos
WO2016160621A3 (en) Nk-92 cells in combination therapy with cancer drugs

Legal Events

Date Code Title Description
FC Refusal